Story
Geron Shares Tumble After Halting Late-Stage Myelofibrosis Drug Trial

Geron Corporation (Nasdaq: GERN) shares plunged in pre-market trading after the company announced it was discontinuing a late-stage clinical trial for its drug imetelstat in patients with myelofibrosis. The decision followed a recommendation from an independent monitoring committee that concluded the study was unlikely to demonstrate a survival benefit.
Trial Halted on Efficacy Concerns
Geron disclosed it would halt its Phase 3 IMpactMF trial based on the advice of an independent Data Monitoring Committee (DMC). The committee determined that the trial was unlikely to achieve its primary endpoint of overall survival.
Key details of the discontinued trial include:
- Drug: Imetelstat
- Indication: Myelofibrosis in patients who had relapsed after or were refractory to JAK inhibitor therapy.
- Patient Enrollment: 327 participants.
- Reason for Halt: Lack of efficacy, not safety. The company specified that no new safety signals were identified by the DMC.
Market Reaction
AdThe announcement triggered a sharp sell-off in the company's stock, which fell 10.4% to $1.03 in pre-open trading. The decline was preceded by a brief trading halt on the Nasdaq at 7:55 a.m. ET pending the news release.
The stock was already trading near its 52-week low of $1.04, a factor that likely intensified the negative reaction. The move was entirely company-driven, as the broader market, including the S&P 500 and Nasdaq, posted modest gains during the same session.
Strategic Setback for Geron
The trial's failure is a significant strategic blow, as a successful outcome in myelofibrosis would have represented a major commercial expansion for imetelstat. The drug is currently approved under the brand name RYTELO for patients with lower-risk myelodysplastic syndromes (MDS).
With this potential growth catalyst now removed, investor focus will likely shift entirely to the commercial performance and sales trajectory of RYTELO in its approved indication. The company's upcoming third-quarter earnings report will be a key event for assessing the drug's launch progress.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.